» Articles » PMID: 34254147

A Diagnosis and Biotype Comparison Across the Psychosis Spectrum: Investigating Volume and Shape Amygdala-Hippocampal Differences from the B-SNIP Study

Overview
Journal Schizophr Bull
Specialty Psychiatry
Date 2021 Jul 13
PMID 34254147
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Brain-based Biotypes for psychotic disorders have been developed as part of the B-SNIP consortium to create neurobiologically distinct subgroups within idiopathic psychosis, independent from traditional phenomenological diagnostic methods. In the current study, we aimed to validate the Biotype model by assessing differences in volume and shape of the amygdala and hippocampus contrasting traditional clinical diagnoses with Biotype classification.

Methods: A total of 811 participants from 6 sites were included: probands with schizophrenia (n = 199), schizoaffective disorder (n = 122), psychotic bipolar disorder with psychosis (n = 160), and healthy controls (n = 330). Biotype classification, previously developed using cognitive and electrophysiological data and K-means clustering, was used to categorize psychosis probands into 3 Biotypes, with Biotype-1 (B-1) showing reduced neural salience and severe cognitive impairment. MAGeT-Brain segmentation was used to determine amygdala and hippocampal volumetric data and shape deformations.

Results: When using Biotype classification, B-1 showed the strongest reductions in amygdala-hippocampal volume and the most widespread shape abnormalities. Using clinical diagnosis, probands with schizophrenia and schizoaffective disorder showed the most significant reductions of amygdala and hippocampal volumes and the most abnormal hippocampal shape compared with healthy controls. Biotype classification provided the strongest neuroanatomical differences compared with conventional DSM diagnoses, with the best discrimination seen using bilateral amygdala and right hippocampal volumes in B-1.

Conclusion: These findings characterize amygdala and hippocampal volumetric and shape abnormalities across the psychosis spectrum. Grouping individuals by Biotype showed greater between-group discrimination, suggesting a promising approach and a favorable target for characterizing biological heterogeneity across the psychosis spectrum.

Citing Articles

Impulsivity in ADHD and Borderline Personality Disorder: A Systematic Review of Gray and White Matter Variations.

Franczak L, Podwalski P, Wysocki P, Dawidowski B, Jedrzejewski A, Jablonski M J Clin Med. 2024; 13(22).

PMID: 39598050 PMC: 11594719. DOI: 10.3390/jcm13226906.


Categorical and Dimensional Approaches for Psychiatric Classification and Treatment Targeting: Considerations from Psychosis Biotypes.

Clementz B, Assaf M, Sweeney J, Gershon E, Keedy S, Hill S Adv Neurobiol. 2024; 40:685-723.

PMID: 39562461 DOI: 10.1007/978-3-031-69491-2_23.


The Modern Concept of Schizoaffective Disorder: A Narrative Review.

Pavlichenko A, Petrova N, Stolyarov A Consort Psychiatr. 2024; 5(3):42-55.

PMID: 39526012 PMC: 11542913. DOI: 10.17816/CP15513.


Gaze behaviors during free viewing revealed differences in visual salience processing across four major psychiatric disorders: a mega-analysis study of 1012 individuals.

Miura K, Yoshida M, Morita K, Fujimoto M, Yasuda Y, Yamamori H Mol Psychiatry. 2024; .

PMID: 39394456 DOI: 10.1038/s41380-024-02773-5.


Combining neuroimaging and brain stimulation to test alternative causal pathways for nicotine addiction in schizophrenia.

Du X, Choa F, Chiappelli J, Bruce H, Kvarta M, Summerfelt A Brain Stimul. 2024; 17(2):324-332.

PMID: 38453003 PMC: 11445730. DOI: 10.1016/j.brs.2024.02.020.


References
1.
Bearden C, Thompson P, Dutton R, Frey B, Peluso M, Nicoletti M . Three-dimensional mapping of hippocampal anatomy in unmedicated and lithium-treated patients with bipolar disorder. Neuropsychopharmacology. 2007; 33(6):1229-38. PMC: 6693586. DOI: 10.1038/sj.npp.1301507. View

2.
Mahon P, Lee D, Trinh H, Tward D, Miller M, Younes L . Morphometry of the amygdala in schizophrenia and psychotic bipolar disorder. Schizophr Res. 2015; 164(1-3):199-202. PMC: 4439197. DOI: 10.1016/j.schres.2015.02.011. View

3.
Makowski C, Bodnar M, Shenker J, Malla A, Joober R, Chakravarty M . Linking persistent negative symptoms to amygdala-hippocampus structure in first-episode psychosis. Transl Psychiatry. 2017; 7(8):e1195. PMC: 5611735. DOI: 10.1038/tp.2017.168. View

4.
Keefe R, Goldberg T, Harvey P, Gold J, Poe M, Coughenour L . The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004; 68(2-3):283-97. DOI: 10.1016/j.schres.2003.09.011. View

5.
Pearlson G, Clementz B, Sweeney J, Keshavan M, Tamminga C . Does Biology Transcend the Symptom-based Boundaries of Psychosis?. Psychiatr Clin North Am. 2016; 39(2):165-74. PMC: 4955658. DOI: 10.1016/j.psc.2016.01.001. View